Form 4: Centessa CPO's Equity Moves: RSU Vesting & Option Grant

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, reported the vesting of restricted share units, a tax-related share disposition, and the grant of new share options.

Summary

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals plc, reported a disposition of 10,606 Ordinary Shares on February 1, 2026, at a price of $24.57 per share.
• This disposition was made to cover tax withholding obligations related to the vesting of restricted share units.
• On February 2, 2026, Anderson acquired 29,000 Ordinary Shares in the form of Restricted Share Units (RSUs) at a price of $0.
• These RSUs will vest in four equal annual installments, with the first vesting on February 2, 2027.
• Additionally, Anderson acquired 117,000 Share Options on February 2, 2026, at an exercise price of $25.19 per share.
• These share options will vest in 1/48th equal monthly installments, with the first installment vesting on March 2, 2026.
• Following these transactions, Anderson beneficially owns 72,716 Ordinary Shares and 117,000 Share Options.
• A Substitute Power of Attorney was filed, appointing Raphael Deferiere as substitute attorney-in-fact for several individuals, including Karen M. Anderson, for SEC filings, effective August 11, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine filing. While there's a share disposition for tax, the significant grants of new RSUs and options demonstrate continued executive alignment and incentive, which is generally favorable.

Positives

• The grant of 29,000 Restricted Share Units (RSUs) and 117,000 Share Options aligns management's interests with shareholders, indicating continued commitment to the company's long-term performance.
• The acquisition of new equity compensation demonstrates ongoing confidence in the company's future prospects by a key executive.

Negatives

• The disposition of 10,606 Ordinary Shares, while standard for tax withholding, reduces the executive's direct shareholding in the short term.

Future Outlook

The filing details future vesting schedules for the granted Restricted Share Units (RSUs) and Share Options, indicating that RSUs will vest annually starting February 2, 2027, and options will vest monthly starting March 2, 2026. This reflects a long-term incentive structure for the Chief People Officer.

Industry Context

StockSavvy.ai notes that the reported transactions are typical for executive compensation in the biotechnology and pharmaceutical industry, where equity-based incentives like Restricted Share Units and stock options are commonly used to attract, retain, and motivate key personnel, aligning their interests with long-term shareholder value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the Chief People Officer's financial interests with the company's long-term performance, potentially fostering greater commitment to shareholder value.
• Employees: The compensation structure for a key executive may serve as a benchmark or signal for broader employee incentive programs, though this filing is specific to one officer.

Next Steps

• The 29,000 Restricted Share Units will begin their four equal annual vesting installments on February 2, 2027.
• The 117,000 Share Options will begin vesting in 1/48th equal monthly installments on March 2, 2026.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Transaction, Restricted Share Units, RSUs, Share Options, Equity Compensation, Chief People Officer, Karen M. Anderson